LimFlow develops the LimFlow System, a minimally invasive family of transcatheter products designed to optimize perfusion of the critically ischemic foot and potentially avoid major amputation. The LimFlow System has FDA Breakthrough Technology designation, received the CE Mark and is commercially available in Europe while approved only for investigational use in the U.S.; it has not been approved for sale in the USA, Canada, or Japan. Proceeds from the Series D financing will fund follow-up for the PROMISE II U.S. pivotal trial necessary to obtain FDA approval and will support commercialization of the LimFlow System for deep vein arterialization. The company recently completed enrollment in PROMISE II and in CLariTI, a natural history study of high-risk and no-option CLTI patients, and integrated a second-generation LimFlow System into its clinical program. LimFlow reported positive two-year data from its PROMISE I U.S. feasibility study. The technology is designed to bypass blocked arteries by delivering oxygenated blood back into the foot via the veins to resolve pain, promote wound healing and prevent major amputation. LimFlow develops a proprietary, CE‑marked percutaneous Deep Vein Arterialization (pDVA) System intended to bypass blocked leg arteries and restore oxygenated blood to the foot for "no-option" CLI patients. The technology is commercially available in Europe and approved for investigational use only in the United States. The company has been accepted into the FDA Breakthrough Devices Program and is enrolling patients in a U.S. feasibility study (PROMISE I) and an international post‑market study (PROMISE International). Proceeds from the recent financing are earmarked to complete a U.S. pivotal trial and support international commercialization. LimFlow is based in Paris and was founded in late 2012 by Dr. Martin Rothman and MD Start.

Total raised

$73M

Funding rounds

2

Latest round

Series D

Latest activity

Apr 2022